Green Cross Cell Acquires Patent for Mesothelin Chimeric Antigen Receptor and T Cell Technologies
[Asia Economy Reporter Minwoo Lee] Green Cross Cell announced on the 9th that it has obtained a patent for 'Mesothelin-specific chimeric antigen receptor and T cells expressing the same.'
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
The company stated, "The chimeric antigen receptor according to this invention has excellent mesothelin-specific targeting efficiency and sustained expression rate, and the T cells expressing the chimeric antigen receptor migrate to and infiltrate target tumors, showing high anticancer activity and excellent persistence. Utilizing this patent, we are developing a CAR-T therapy with superior anticancer effects against solid tumors," it explained.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
